Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) has released the final data assessment from its Phase 2 clinical trial evaluating the combo of ELX-02 + ivacaftor in Class 1 cystic fibrosis (CF) patients with at least one nonsense mutation. 

In the final assessment, ELX-02 showed a clinically relevant improvement in percent predicted forced expiratory volume (ppFEV1). These findings on ELX-02, along with the successful Phase 2 trial for Alport syndrome, have strengthened Eloxx's decision to proceed with a pivotal trial in treating this genetic disorder, which is characterized by kidney disease, proteinuria, hearing loss, and eye abnormalities, affecting a subset of patients with nonsense mutations who currently lack effective treatment options.

$ELOX was trading at $6.75, down $0.23 (-3.30%) in after-hours, following the announcement

Integral Ad Science Holding Corp. (Nasdaq: IAS) has made a significant expansion by partnering with TikTok, enabling advertisers in 23 new markets to access its Total Media Quality brand safety and suitability measurement product. 

IAS's innovative solution utilizes advanced artificial intelligence (AI) to provide comprehensive insights into video content through frame-by-frame analysis of images, audio, and text, even considering semantics. This level of detail empowers marketers to effectively monitor the quality of their media placements on TikTok, ensuring their ads are displayed alongside brand-safe and suitable content.

Meanwhile, several investment firms continue to maintain their positive outlook on IAS:

Craig-Hallum maintained a Buy rating on IAS, raising the price target from $20 to $23.
Morgan Stanley maintained an Overweight rating, increasing the price target from $20 to $21.5.
Barclays maintained an Equal-Weight rating, raising the price target from $17 to $20.
Oppenheimer maintained an Outperform rating, increasing the price target from $20 to $25.
Raymond James maintained a Strong Buy rating, raising the price target from $19 to $23.

$IAS closed at $19.25 on Wednesday

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)